Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey.
Cameroon
HIV
antiretroviral therapy interruption
intimate partner violence
women
Journal
Women's health (London, England)
ISSN: 1745-5065
Titre abrégé: Womens Health (Lond)
Pays: United States
ID NLM: 101271249
Informations de publication
Date de publication:
Historique:
entrez:
11
6
2019
pubmed:
11
6
2019
medline:
30
1
2020
Statut:
ppublish
Résumé
Intimate partner violence in its various forms increases HIV exposure in female victims and potentially jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence against HIV-positive women and its relationship with antiretroviral therapy interruption ⩾1 month. The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The study sample comprised antiviral therapy-treated women declaring at least one sexual partner in the previous year. Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral therapy interruption ⩾1 month, and associated factors. Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% (physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk factor of antiretroviral therapy interruption ⩾1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-defensive violence against this partner (5.75 (3.53; 9.36)). Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might help to reach the last "90" of the 90-90-90 targets.
Sections du résumé
BACKGROUND
Intimate partner violence in its various forms increases HIV exposure in female victims and potentially jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence against HIV-positive women and its relationship with antiretroviral therapy interruption ⩾1 month.
METHODS
The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The study sample comprised antiviral therapy-treated women declaring at least one sexual partner in the previous year. Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral therapy interruption ⩾1 month, and associated factors.
RESULTS
Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% (physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk factor of antiretroviral therapy interruption ⩾1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-defensive violence against this partner (5.75 (3.53; 9.36)).
CONCLUSION
Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might help to reach the last "90" of the 90-90-90 targets.
Identifiants
pubmed: 31177929
doi: 10.1177/1745506519848546
pmc: PMC6558534
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1745506519848546Références
AIDS Patient Care STDS. 2006 Feb;20(2):122-32
pubmed: 16475893
AIDS Res Ther. 2012 Dec 19;9(1):37
pubmed: 23253095
J Assoc Nurses AIDS Care. 2004 Sep-Oct;15(5 Suppl):20S-27S
pubmed: 15587605
Curr Opin HIV AIDS. 2012 Mar;7(2):117-24
pubmed: 22258501
BMC Public Health. 2011 Feb 16;11:109
pubmed: 21324186
AIDS Behav. 2013 Nov;17(9):2845-63
pubmed: 23934267
Rev Saude Publica. 2010 Aug;44(4):658-66
pubmed: 20676557
J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2:S118-27
pubmed: 25978478
Curr HIV/AIDS Rep. 2013 Dec;10(4):380-9
pubmed: 23943348
AIDS Behav. 2013 Mar;17(3):832-47
pubmed: 23143750
AIDS. 2007 Sep 12;21(14):1957-63
pubmed: 17721103
J Assoc Nurses AIDS Care. 2013 Jul-Aug;24(4):383-90
pubmed: 23790280
Trop Med Int Health. 2011 Oct;16(10):1297-313
pubmed: 21718394
AIDS Behav. 2018 Oct;22(10):3244-3263
pubmed: 29313192
AIDS Patient Care STDS. 2012 Jun;26(6):356-65
pubmed: 22612519
Womens Health Issues. 2012 Nov-Dec;22(6):e563-9
pubmed: 22939089
Trop Med Int Health. 2018 Mar;23(3):315-326
pubmed: 29327419
J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):247-52
pubmed: 10770344
AIDS. 2011 Oct 23;25(16):2009-18
pubmed: 21811146
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):32-8
pubmed: 23714742
Trop Med Int Health. 2007 Dec;12(12):1484-9
pubmed: 18076556
HIV Med. 2014 Sep;15(8):478-87
pubmed: 24589279
N Engl J Med. 2019 Feb 28;380(9):850-857
pubmed: 30811911
Lancet. 2004 May 1;363(9419):1415-21
pubmed: 15121402
Glob Health Action. 2017 Jan - Dec;10(sup2):1290427
pubmed: 28467193
Lancet. 2006 Dec 2;368(9551):1973-83
pubmed: 17141704
Soc Sci Med. 2011 Apr;72(8):1383-92
pubmed: 21470734
Am J Public Health. 2004 Jul;94(7):1147-51
pubmed: 15226135
N Engl J Med. 2006 Nov 30;355(22):2283-96
pubmed: 17135583
AIDS. 2015 Oct 23;29(16):2183-94
pubmed: 26353027
J Int AIDS Soc. 2015 Dec 01;18(Suppl 5):20292
pubmed: 26643462
J Int AIDS Soc. 2014 Feb 13;17:18845
pubmed: 24560342
Lancet. 2002 Apr 20;359(9315):1423-9
pubmed: 11978358
Res Nurs Health. 2001 Dec;24(6):518-29
pubmed: 11746080
AIDS Care. 2010 Mar;22(3):279-85
pubmed: 20390507
Lancet. 2010 Jul 3;376(9734):41-8
pubmed: 20557928
Clin Infect Dis. 2018 May 2;66(10):1487-1491
pubmed: 29324994
Am J Prev Med. 2002 Nov;23(4):260-8
pubmed: 12406480
J Clin Epidemiol. 1998 Nov;51(11):1171-8
pubmed: 9817135
PLoS One. 2011 Mar 08;6(3):e17591
pubmed: 21408120
BMC Med. 2014 Aug 21;12:142
pubmed: 25145556
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS Care. 2011 Jun;23(6):741-7
pubmed: 21293987
J Adv Nurs. 1999 Sep;30(3):606-15
pubmed: 10499217
Clin Infect Dis. 2009 May 1;48(9):1310-7
pubmed: 19309307
Antivir Ther. 2013;18(1):29-37
pubmed: 23358393
BMC Womens Health. 2011 Nov 17;11:50
pubmed: 22093904
PLoS One. 2013 Nov 25;8(11):e81044
pubmed: 24282566
Curr HIV/AIDS Rep. 2015 Dec;12(4):397-405
pubmed: 26419376